IRCT2014120117413N9已完成未知
Preventive Effect of Atorvastatin 80 mg on Contrast Induced Nephropathy after Angiography in High Risk Patients
Baqiyatallah university of medical science0 个研究点目标入组 250 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 55 years 至 75 years（—）
- 性别
- All
入选标准
- •diabetes mellitus (FBS> 126, Random BS> 200, GTT> 200); chronic renal failure (creatinine higher than 1.5 mg/dl or GFR less than 60)
- •Exclusion criteria: recent treatment with statin 80 mg; patients requiring emergency angiography; contraindications to prescribe statins; Patients with previous contrast media administration during the last 10 days; Patients with chronic dialysis treatment; patients with informed refusal of consent
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Effect of Atorvastatin and CoQ10 on strokeischemic stroke.Cerebral infarctionIRCT2017041731773N1Vice chancellor for research, Shahid Beheshti University of Medical Sciences60
已完成
3 期
Impact of ATOrvastatin REload on the Prevention of Contrast-INduced Nephropathy in patients on Chronic Statin Therapy: A prospective randomized trial (ATORE-CIN)renal diseasesPACTR202110707328144hedi chaker hospital102
已完成
3 期
Effect of Atorvastatin in Helicobacter pylori eradicatioHelicobacter pylori infection.IRCT20190823044589N1Oroumia University of Medical Sciences120
招募中
不适用
Evaluation of the effect of Atorvastatin in diabetic type 2 patients in the morning and eveningIRCT20211211053359N1Babol University of Medical Sciences76
进行中（未招募）
1 期
TRial of Atorvastatin for the primary prevention of Cardiovascular Events in Rheumatoid Arthritis - TRACE RARheumatoid arthritis is associated with increased mortality from cardiovascular disease (CVD). Statins have a proven effect in reducing CVD events in at-risk populations, mostly due to their cholesterol-lowering properties, but possibly through anti-inflammatory and immunomodulatory effects. This trial will assess the hypothesis that atorvastatin is more effective than placebo in the primary prevention of cardiovascular events in patients with RA.EUCTR2006-006032-22-GBniversity of Manchester5,350